106 related articles for article (PubMed ID: 9696646)
1. CDKN2A mutations in multiple primary melanomas.
Bystryn JC
N Engl J Med; 1998 Jul; 339(5):347; author reply 348. PubMed ID: 9696646
[No Abstract] [Full Text] [Related]
2. CDKN2A mutations in multiple primary melanomas.
Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
[TBL] [Abstract][Full Text] [Related]
3. The CDKN2A tumor-suppressor locus--a tale of two proteins.
Clurman BE; Groudine M
N Engl J Med; 1998 Mar; 338(13):910-2. PubMed ID: 9516230
[No Abstract] [Full Text] [Related]
4. Role of the CDKN2A locus in patients with multiple primary melanomas.
Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M
J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862
[TBL] [Abstract][Full Text] [Related]
5. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A mutation and deletion status in thin and thick primary melanoma.
Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
[TBL] [Abstract][Full Text] [Related]
9. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
10. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
[TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous melanoma arising in agminated melanocytic nevi: CDKN2A and CDK4 mutation screening.
Rezze GG; Leon A; Silva DC; Neves RI; Molina GC; Carraro DM; Landman G; Duprat JP
Acta Derm Venereol; 2012 Jan; 92(1):98-9. PubMed ID: 21710107
[No Abstract] [Full Text] [Related]
12. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families.
Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T
Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857
[TBL] [Abstract][Full Text] [Related]
13. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation.
Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA
Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
16. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
17. Multiple primary melanoma revisited.
Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A
Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
19. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
[TBL] [Abstract][Full Text] [Related]
20. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]